These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30697570)

  • 41. Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.
    Cressey TR; Avihingsanon A; Halue G; Leenasirimakul P; Sukrakanchana PO; Tawon Y; Jaisieng N; Jourdain G; Podany AT; Fletcher CV; Klinbuayaem V; Bowonwatanuwong C
    Clin Infect Dis; 2015 Aug; 61(4):633-9. PubMed ID: 25921689
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Renal proximal tubulopathy in an HIV-infected patient treated with tenofovir alafenamide and gentamicin: a case report.
    Heron JE; Bloch M; Vanguru V; Saunders J; Gracey DM
    BMC Nephrol; 2020 Aug; 21(1):339. PubMed ID: 32787843
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.
    Cressey TR; Siriprakaisil O; Klinbuayaem V; Quame-Amaglo J; Kubiak RW; Sukrakanchana PO; Than-In-At K; Baeten J; Sirirungsi W; Cressey R; Drain PK
    BMC Infect Dis; 2017 Jul; 17(1):496. PubMed ID: 28705153
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
    Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
    AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tenofovir disoproxil fumarate co-administered with lopinavir/ritonavir is strongly associated with tubular damage and chronic kidney disease.
    Mizushima D; Nguyen DTH; Nguyen DT; Matsumoto S; Tanuma J; Gatanaga H; Trung NV; van Kinh N; Oka S
    J Infect Chemother; 2018 Jul; 24(7):549-554. PubMed ID: 29602711
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Polymorphisms of tenofovir disoproxil fumarate transporters and risk of kidney tubular dysfunction in HIV-positive patients: genetics of tenofovir transporters.
    Danjuma MI; Egan D; Abubeker IY; Post F; Khoo S
    Int J STD AIDS; 2018 Aug; ():956462418786562. PubMed ID: 30071797
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide.
    Lalley-Chareczko L; Hiserodt E; Moorthy G; Zuppa A; Mounzer K; Koenig H
    Front Pharmacol; 2020; 11():286. PubMed ID: 32265700
    [No Abstract]   [Full Text] [Related]  

  • 48. Renal Toxicity of Concomitant Exposure to Tenofovir and Inhibitors of Tenofovir's Renal Efflux Transporters in Patients Infected With HIV Type 1.
    Rokx C; Alshangi H; Verbon A; Zietse R; Hoorn EJ; Rijnders BJ
    J Infect Dis; 2016 Feb; 213(4):561-8. PubMed ID: 26401025
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy.
    Liu CH; Sun HY; Hsieh SM; Liu WC; Sheng WH; Liu CJ; Su TH; Tseng TC; Chen PJ; Hung CC; Kao JH
    J Viral Hepat; 2021 Jun; 28(6):887-896. PubMed ID: 33759290
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies.
    Winston J; Chonchol M; Gallant J; Durr J; Canada RB; Liu H; Martin P; Patel K; Hindman J; Piontkowsky D
    HIV Clin Trials; 2014; 15(6):231-45. PubMed ID: 25433663
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tenofovir-induced renal tubular dysfunction among human immunodeficiency virus patients on antiretroviral therapy in Nigeria: Prospects for early detection of presymptomatic nephrotoxicity.
    Obiebi IP; Nwannadi EA
    Kidney Res Clin Pract; 2018 Sep; 37(3):230-238. PubMed ID: 30254847
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection.
    Bedimo R; Rosenblatt L; Myers J
    HIV Clin Trials; 2016 Nov; 17(6):246-266. PubMed ID: 27809711
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
    Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
    Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis.
    Wang H; Lu X; Yang X; Xu N
    Medicine (Baltimore); 2016 Oct; 95(41):e5146. PubMed ID: 27741146
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir.
    Yilma D; Abdissa A; Kæstel P; Tesfaye M; Olsen MF; Girma T; Ritz C; Friis H; Andersen ÅB; Kirk O
    BMC Infect Dis; 2020 Aug; 20(1):582. PubMed ID: 32762646
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tenofovir disoproxil fumarate initiation and changes in urinary biomarker concentrations among HIV-infected men and women.
    Zhang WR; Scherzer R; Estrella MM; Ascher SB; Muiru A; Jotwani V; Grunfeld C; Parikh CR; Gustafson D; Kassaye S; Sharma A; Cohen M; Tien PC; Ng DK; Palella FJ; Witt MD; Ho K; Shlipak MG
    AIDS; 2019 Mar; 33(4):723-733. PubMed ID: 30830887
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
    Tao X; Lu Y; Zhou Y; Zhang L; Chen Y
    Int J Infect Dis; 2020 Apr; 93():108-117. PubMed ID: 31988012
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.
    Li B; Liu Z; Liu X; Liu D; Duan M; Gu Y; Liu Q; Ma Q; Wei Y; Wang Y
    Hepatol Int; 2021 Oct; 15(5):1103-1108. PubMed ID: 34312798
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
    DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
    Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection.
    Huang YS; Chang SY; Sheng WH; Sun HY; Lee KY; Chuang YC; Su YC; Liu WC; Hung CC; Chang SC
    PLoS One; 2016; 11(12):e0169228. PubMed ID: 28033344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.